

### Announcement 8 March 2010

## Coloplast – transactions in connection with share buy-back programme

As informed in Announcement No. 2/2010 the shareholders in general meeting in December 2009 authorised Coloplast to establish a share buy-back programme of up to DKK 1bn during 2010 and 2011. The first part of DKK 500m will be exercised in the period from 15 February 2010 to 30 September 2010.

Under the programme the following transactions have been executed during the period 1-5 March 2010:

Date	Number of shares	Average buying price	Amount DKK
1.3.2010	9,550	624.51	5,964,070.50
2.3.2010	15,000	620.34	9,305,100.00
3.3.2010	9,731	624.34	6,075,452.54
4.3.2010	12,586	634.50	7,985,817.00
5.3.2010	12,390	638.56	7,911,758.40
Accumulated until now			
under the programme	127,533	618.33	78,858,079.29

Henceforth, Coloplast owns 2,169,303 own B shares of DKK 5 equal to 4.82% of the company's total share capital.

Share buy-back in the amount of DKK 421,141,920.71 remains under the first part of the programme.



Ostomy Care Urology & Continence Care Wound & Skin Care

# For further information, please contact

#### Investors and analysts

Lene Skole Executive Vice President, CFO Tel. +45 4911 1700

Ian S.E. Christensen Director of Investor Relations Tel. +45 4911 1800/+45 4911 1301 Email: dkisec@coloplast.com

### Press and the media

Morten Sørensen Media Relations Manager Tel. +45 4911 2632 Email: dkmoso@coloplast.com

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2010-03 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology and Continence Care and Wound and Skin Care. We operate globally and employ more than 7,000 people.